Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as the company’s Chief Executive Officer (CEO) and a member of the Board.
 
As Co-Founder and CSO, Osbourn has led all aspects of Alchemab’s platform development and drug discovery activities to date and brings to the CEO role more than 30 years of biopharmaceutical industry experience.
 
Prior to co-founding Alchemab in 2019, Osbourn served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology and the discovery and development of several marketed antibody therapies including HUMIRA (adalimumab) and IMFINZI (durvalumab).
 
She is a Venture Partner at SV Health Investors, has served as a Director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, and was Chair of the Board of Directors of the UK BioIndustry Association.
 
In 2019, Osbourn was awarded an Order of the British Empire (OBE) and Scrip’s Lifetime Achievement Award for services to drug discovery, development and biotechnology.
 
“I have had the great pleasure of helping to lead the Company since the beginning,” said Osbourn. “We have a fantastic team who have been integral to Alchemab’s growth from a concept through to a robust and novel antibody identifying engine. With several novel targets and therapeutic antibodies in preclinical development, I am delighted to lead Alchemab as CEO through this next phase towards achieving our ultimate goal of discovering and developing ground-breaking treatments for patients.”
 
Young Kwon, outgoing CEO of Alchemab, commented: “The time is right to hand over the reins to Jane to lead the Company as CEO. Jane has been my partner in growing Alchemab and has played a central role in establishing the Company’s robust, well-tuned antibody discovery platform. I am very pleased to hand over to Jane whose scientific and organizational expertise will ensure the successful progress of Alchemab as it enters its next phase of growth.”